The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11110 malaria professionals are enjoying the free benefits of MalariaWorld today

Ex vivo

Questioning the Claimed Superiority of Malaria Parasite Ex Vivo Viability Reduction Over Observed Parasite Clearance Rate

August 17, 2021 - 14:14 -- Open Access
Author(s): 
White NJ, Watson JA
Reference: 
J Infect Dis. 2021 Aug 16;224(4):738-739

To the Editor—In a study of 10 Plasmodium falciparum–infected volunteers with submicroscopic parasitemias given a single 200-mg dose of artesunate, Rebelo et al [1] reported a substantial difference in the ex vivo growth of sequentially sampled circulating ring-stage [2] parasites comparing infections with artemisinin-sensitive (Pfkelch wild-type) and artemisinin-resistant (Pfkelch R539T) parasites.

Chloroquine Potentiates Primaquine Activity Against Active and Latent Hepatic Plasmodia Ex vivo: Potentials and Pitfalls

October 21, 2020 - 09:26 -- Open Access
Author(s): 
Dembélé L, Franetich JF, Snounou G, et al.
Reference: 
Antimicrob Agents Chemother. 2020 Oct 19:AAC.01416-20

8-aminoquinoline compounds have long been the only therapeutic agents against latent hepatic malaria parasites. These have poor activity against the blood stage plasmodia causing acute malaria and must be used in conjunction with partner blood schizontocidal agents. We examined the impacts of one such agent, chloroquine, upon the activity of primaquine, an 8-aminoquinoline, against hepatic stages of Plasmodium cynomolgi, Plasmodium yoelii, Plasmodium berghei, and Plasmodium falciparum within several ex vivo systems: primary hepatocytes of Macaca fascicularis; primary human hepatocytes; and stably transformed human hepatocarcinoma cell line HepG2.

NOT Open Access | Pharmacokinetics and Ex vivo Antimalarial Activity of Artesunate-Amodiaquine plus Methylene Blue in Healthy Volunteers

January 27, 2020 - 13:47 -- NOT Open Access
Author(s): 
Anh CX, Chavchich M, Birrell GW, Van Breda K, Travers T, Rowcliffe K, Lord AR, Shanks GD, Edstein MD
Reference: 
Antimicrob Agents Chemother. 2020 Jan 6. pii: AAC.01441-19

High artesunate combination therapy (ACT) treatment failures of Plasmodium falciparum malaria in Southeast Asia has led to triple drug strategies to extend the useful life of ACTs. In this study, we determined whether methylene blue (MB) alters the pharmacokinetics of artesunate-amodiaquine (ASAQ) and enhances the ex vivo antimalarial activity of ASAQ. In an open labelled, randomized cross-over design, a single oral dose of either ASAQ (200 mg AS/540 mg AQ) alone or with MB (325 mg MB) was administered to 15 healthy Vietnamese volunteers. Serial blood samples were collected up to 28 days after dosing.


NOT Open Access | Ex vivo efficacy of selective chalcone derivatives on reference strains and field isolates of Plasmodium falciparum

January 14, 2020 - 12:12 -- NOT Open Access
Author(s): 
Dable MT, Tano KD, Ouattara M, Silue KD, Menan EIH, Yavo W
Reference: 
Pathogens and Global Health, 2020 Jan 7:1-5

The extension of Plasmodium falciparum resistance to existing antimalarial drugs is worrying. Faced with this problem, the search for new and effective molecules is necessary. In this context, six chalcone derivatives (B1, B11, B14, B17, SCA02 and SCA03) were tested on field isolates and then reference strains to evaluate their antiplasmodial activity by using the Rieckmann semi-microtest, recommended by WHO, for in vitro and ex vivo activity tests.

Subscribe to RSS - Ex vivo